Listing of Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

1. (Currently Amended) A compound of formula (I),



(I)

the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein

n is 0, 1, 2 or 3 and when n is 0 then a direct bond is intended;

t is 0, 1, 2, 3 or 4 and when t is 0 then a direct bond is intended;

each Q is ~~nitrogen or~~  ;

each X is nitrogen ~~or~~  ;

each Y is nitrogen ~~or~~  ;

each Z is nitrogen ~~or~~  ;

R^1 is –C(O)NR^7R^8, -NHC(O)R^9, -C(O)-C_{1-6}alkanediylSR^9, -NR^{10}C(O)N(OH)R^9, -NR^{10}C(O)C_{1-6}alkanediylSR^9, -NR^{10}C(O)C=N(OH)R^9 or another Zn-chelating-group wherein R^7 and R^8 are each independently selected from hydrogen, hydroxy, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, aminoC_{1-6}alkyl or aminoaryl;
R^9 is independently selected from hydrogen, C_{1-6}alkyl, C_{1-6}alkylcarbonyl, arylC_{1-6}alkyl, C_{1-6}alkylpyrazinyl, pyridinone, pyrrolidinone or methylimidazolyl;
R^{10} is independently selected from hydrogen or C_{1-6}alkyl;

R^2 is hydrogen, halo, hydroxy, amino, nitro, C_{1-6}alkyl, C_{1-6}alkyloxy, trifluoromethyl, di(C_{1-6}alkyl)amino, hydroxyamino or naphtalenylsulfonylpyrazinyl;

-L- is a direct bond or a bivalent radical selected from C_{1-6}alkanediyl, C_{1-6}alkanediyloxy, amino, carbonyl or aminocarbonyl;

each R^3 independently represents a hydrogen atom and one hydrogen atom can be replaced by a substituent selected from aryl;

R^4 is hydrogen, hydroxy, amino, hydroxyC_{1-6}alkyl, C_{1-6}alkyl, C_{1-6}alkyloxy, arylC_{1-6}alkyl, aminocarbonyl, hydroxycarbonyl, aminoC_{1-6}alkyl, aminocarbonylC_{1-6}alkyl, hydroxycarbonylC_{1-6}alkyl, hydroxyaminocarbonyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylaminoC_{1-6}alkyl or di(C_{1-6}alkyl)aminoC_{1-6}alkyl;

—(A) is a radical selected from



(a-1)



(a-2)



(a-3)



(a-4)



(a-5)



(a-6)



(a-7)



(a-8)



(a-9)



(a-10)



(a-11)



(a-12)



(a-13)



(a-14)



(a-15)



(a-16)



(a-17)



(a-18)



(a-19)



(a-20)



(a-21)



(a-22)



(a-23)



(a-24)



(a-25)



(a-26)



(a-27)



(a-28)



(a-29)



(a-30)



(a-31)



(a-32)



(a-33)



(a-34)



(a-35)



(a-36)


(a-37)


(a-38)


(a-39)


(a-40)


(a-41)


(a-42)


(a-43)


(a-44)


(a-45)


(a-46)


(a-47)


(a-48)


(a-49)


(a-50)


(a-51)

wherein each s is independently 0, 1, 2, 3, 4 or 5;

each R^5 and R^6 are independently selected from hydrogen; halo; hydroxy; amino; nitro; trihaloC_{1-6}alkyl; trihaloC_{1-6}alkyloxy; C_{1-6}alkyl; C_{1-6}alkyl substituted with aryl and C_{3-10}cycloalkyl; C_{1-6}alkyloxy; C_{1-6}alkyloxyC_{1-6}alkyloxy; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkylsulfonyl; cyanoC_{1-6}alkyl; hydroxyC_{1-6}alkyl; hydroxyC_{1-6}alkyloxy; hydroxyC_{1-6}alkylamino; aminoC_{1-6}alkyloxy; di(C_{1-6}alkyl)aminocarbonyl; di(hydroxyC_{1-6}alkyl)amino; (aryl)(C_{1-6}alkyl)amino; di(C_{1-6}alkyl)aminoC_{1-6}alkyloxy; di(C_{1-6}alkyl)aminoC_{1-6}alkylamino; di(C_{1-6}alkyl)aminoC_{1-6}alkylaminoC_{1-6}alkyl; arylsulfonyl; arylsulfonylamino; aryloxy; aryloxyC_{1-6}alkyl; arylC_{2-6}alkenediyl; di(C_{1-6}alkyl)amino; di(C_{1-6}alkyl)aminoC_{1-6}alkyl; di(C_{1-6}alkyl)amino(C_{1-6}alkyl)amino; di(C_{1-6}alkyl)amino(C_{1-6}alkyl)aminoC_{1-6}alkyl;

di(C_{1-6}alkyl)aminoC_{1-6}alkyl(C_{1-6}alkyl)amino;
di(C_{1-6}alkyl)aminoC_{1-6}alkyl(C_{1-6}alkyl)aminoC_{1-6}alkyl;
aminosulfonylamino(C_{1-6}alkyl)amino;
aminosulfonylamino(C_{1-6}alkyl)aminoC_{1-6}alkyl;
di(C_{1-6}alkyl)aminosulfonylamino(C_{1-6}alkyl)amino;
di(C_{1-6}alkyl)aminosulfonylamino(C_{1-6}alkyl)aminoC_{1-6}alkyl; cyano; thiophenyl; thiophenyl substituted with di(C_{1-6}alkyl)aminoC_{1-6}alkyl(C_{1-6}alkyl)aminoC_{1-6}alkyl, di(C_{1-6}alkyl)aminoC_{1-6}alkyl, C_{1-6}alkylpiperazinylC_{1-6}alkyl,
hydroxyC_{1-6}alkylpiperazinylC_{1-6}alkyl,
hydroxyC_{1-6}alkyloxyC_{1-6}alkylpiperazinylC_{1-6}alkyl,
di(C_{1-6}alkyl)aminosulfonylpiperazinylC_{1-6}alkyl,
C_{1-6}alkyloxypiperidinyl, C_{1-6}alkyloxypiperidinylC_{1-6}alkyl, morpholinylC_{1-6}alkyl,
hydroxyC_{1-6}alkyl(C_{1-6}alkyl)aminoC_{1-6}alkyl, or di(hydroxyC_{1-6}alkyl)aminoC_{1-6}alkyl;
furanyl; furanyl substituted with hydroxyC_{1-6}alkyl; benzofuranyl; imidazolyl; oxazolyl;
oxazolyl substituted with aryl and C_{1-6}alkyl; C_{1-6}alkyltriazolyl; tetrazolyl; pyrrolidinyl;
pyrrolyl; piperidinylC_{1-6}alkyloxy; morpholinyl; C_{1-6}alkylmorpholinyl; morpholinylC_{1-6}alkyloxy;
morpholinylC_{1-6}alkyl; morpholinylC_{1-6}alkylamino;
morpholinylC_{1-6}alkylaminoC_{1-6}alkyl; piperazinyl; C_{1-6}alkylpiperazinyl;
C_{1-6}alkylpiperazinylC_{1-6}alkyloxy; piperazinylC_{1-6}alkyl; naphtalenylsulfonylpiperazinyl;
naphtalenylsulfonylpiperidinyl; naphtalenylsulfonyl;
C_{1-6}alkylpiperazinylC_{1-6}alkyl; C_{1-6}alkylpiperazinylC_{1-6}alkylamino;
C_{1-6}alkylpiperazinylC_{1-6}alkylaminoC_{1-6}alkyl; C_{1-6}alkylpiperazinylsulfonyl;
aminosulfonylpiperazinylC_{1-6}alkyloxy; aminosulfonylpiperazinyl;
aminosulfonylpiperazinylC_{1-6}alkyl; di(C_{1-6}alkyl)aminosulfonylpiperazinyl;
di(C_{1-6}alkyl)aminosulfonylpiperazinylC_{1-6}alkyl; hydroxyC_{1-6}alkylpiperazinyl; hydroxyC_{1-6}alkylpiperazinylC_{1-6}alkyl; C_{1-6}alkyloxypiperidinyl;
C_{1-6}alkyloxypiperidinylC_{1-6}alkyl; piperidinylaminoC_{1-6}alkylamino; piperidinylaminoC_{1-6}alkylaminoC_{1-6}alkyl;
(C_{1-6}alkylpiperidinyl)(hydroxyC_{1-6}alkyl)aminoC_{1-6}alkylamino;
(C_{1-6}alkylpiperidinyl)(hydroxyC_{1-6}alkyl)aminoC_{1-6}alkylaminoC_{1-6}alkyl;
hydroxyC_{1-6}alkyloxyC_{1-6}alkylpiperazinyl;
hydroxyC_{1-6}alkyloxyC_{1-6}alkylpiperazinylC_{1-6}alkyl;
(hydroxyC_{1-6}alkyl)(C_{1-6}alkyl)amino; (hydroxyC_{1-6}alkyl)(C_{1-6}alkyl)aminoC_{1-6}alkyl;
hydroxyC_{1-6}alkylaminoC_{1-6}alkyl; di(hydroxyC_{1-6}alkyl)aminoC_{1-6}alkyl;

pyrrolidinylC_{1-6}alkyl; pyrrolidinylC_{1-6}alkyloxy; pyrazolyl; thiopyrazolyl; pyrazolyl substituted with two substituents selected from C_{1-6}alkyl or trihaloC_{1-6}alkyl; pyridinyl; pyridinyl substituted with C_{1-6}alkyloxy, aryloxy or aryl; pyrimidinyl; tetrahydropyrimidinylpiperazinyl; tetrahydropyrimidinylpiperazinylC_{1-6}alkyl; quinolinyl; indole; phenyl; phenyl substituted with one, two or three substituents independently selected from halo, amino, nitro, C_{1-6}alkyl, C_{1-6}alkyloxy, hydroxyC_{1-4}alkyl, trifluoromethyl, trifluoromethyloxy, hydroxyC_{1-4}alkyloxy, C_{1-4}alkylsulfonyl, C_{1-4}alkyloxyC_{1-4}alkyloxy, C_{1-4}alkyloxycarbonyl, aminoC_{1-4}alkyloxy, di(C_{1-4}alkyl)aminoC_{1-4}alkyloxy, di(C_{1-4}alkyl)amino, di(C_{1-4}alkyl)aminocarbonyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)amino(C_{1-4}alkyl)amino, di(C_{1-4}alkyl)amino(C_{1-4}alkyl)aminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkyl(C_{1-4}alkyl)amino, di(C_{1-4}alkyl)aminoC_{1-4}alkyl(C_{1-4}alkyl)aminoC_{1-4}alkyl, aminosulfonylamino(C_{1-4}alkyl)amino, aminosulfonylamino(C_{1-4}alkyl)aminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminosulfonylamino(C_{1-4}alkyl)amino, di(C_{1-4}alkyl)aminosulfonylamino(C_{1-4}alkyl)aminoC_{1-6}alkyl, cyano, piperidinylC_{1-4}alkyloxy, pyrrolidinylC_{1-4}alkyloxy, aminosulfonylpiperazinyl, aminosulfonylpiperazinylC_{1-4}alkyl, di(C_{1-4}alkyl)aminosulfonylpiperazinyl, di(C_{1-4}alkyl)aminosulfonylpiperazinylC_{1-4}alkyl, hydroxyC_{1-4}alkylpiperazinyl, hydroxyC_{1-4}alkylpiperazinylC_{1-4}alkyl, C_{1-4}alkyloxypiperidinyl, C_{1-4}alkyloxypiperidinylC_{1-4}alkyl, hydroxyC_{1-4}alkyloxyC_{1-4}alkylpiperazinyl, hydroxyC_{1-4}alkyloxyC_{1-4}alkylpiperazinylC_{1-4}alkyl, (hydroxyC_{1-4}alkyl)(C_{1-4}alkyl)amino, (hydroxyC_{1-4}alkyl)(C_{1-4}alkyl)aminoC_{1-4}alkyl, di(hydroxyC_{1-4}alkyl)amino, di(hydroxyC_{1-4}alkyl)aminoC_{1-4}alkyl, furanyl, furanyl substituted with –CH=CH-CH=CH-, pyrrolidinylC_{1-4}alkyl, pyrrolidinylC_{1-4}alkyloxy, morpholinyl, morpholinylC_{1-4}alkyloxy, morpholinylC_{1-4}alkyl, morpholinylC_{1-4}alkylamino, morpholinylC_{1-4}alkylaminoC_{1-4}alkyl, piperazinyl, C_{1-4}alkylpiperazinyl, C_{1-4}alkylpiperazinylC_{1-4}alkyloxy, piperazinylC_{1-4}alkyl, C_{1-4}alkylpiperazinylC_{1-4}alkyl, C_{1-4}alkylpiperazinylC_{1-4}alkylamino, C_{1-4}alkylpiperazinylC_{1-4}alkylaminoC_{1-6}alkyl, tetrahydropyrimidinylpiperazinyl, tetrahydropyrimidinylpiperazinylC_{1-4}alkyl, piperidinylaminoC_{1-4}alkylamino, piperidinylaminoC_{1-4}alkylaminoC_{1-4}alkyl, (C_{1-4}alkylpiperidinyl)(hydroxyC_{1-4}alkyl)aminoC_{1-4}alkylamino,

(C_{1-4}alkylpiperidinyl)(hydroxyC_{1-4}alkyl)aminoC_{1-4}alkylaminoC_{1-4}alkyl, pyridinylC_{1-4}alkyloxy, hydroxyC_{1-4}alkylamino, hydroxyC_{1-4}alkylaminoC_{1-4}alkyl, di(C_{1-4}alkyl)aminoC_{1-4}alkylamino, aminothiadiazolyl, aminosulfonylpiperazinylC_{1-4}alkyloxy, or thiophenylC_{1-4}alkylamino;

each R^5 and R^6 can be placed on the nitrogen in replacement of the hydrogen;

aryl in the above is phenyl, or phenyl substituted with one or more substituents each independently selected from halo, C_{1-6}alkyl, C_{1-6}alkyloxy, trifluoromethyl, cyano or hydroxycarbonyl.

2. (Original) A compound as claimed in claim 1 wherein n is 1 or 2; t is 0, 1, 2 or 4; each Q is —C≪; R^1 is –C(O)NH(OH); R^2 is hydrogen or nitro; -L- is a direct bond or a bivalent radical selected from C_{1-6}alkanediyl; R^4 is hydrogen; —(A) is a radical selected from (a-1),(a-2), (a-3), (a-5), (a-6), (a-11), (a-18), (a-20), (a-21), (a-32), (a-33), (a-47) or (a-51); each s is independently 0, 1, 2, or 4; each R^5 and R^6 are independently selected from hydrogen; halo; trihaloC_{1-6}alkyl; C_{1-6}alkyl; C_{1-6}alkyl substituted with aryl and C_{3-10}cycloalkyl; C_{1-6}alkyloxy; C_{1-6}alkylcarbonyl; benzofuranyl; naphtalenylsulfonyl; pyridinyl substituted with aryloxy; phenyl; or phenyl substituted with one substituent independently selected from hydroxyC_{1-4}alkyl or morpholinylC_{1-4}alkyl.

3. (Original) A compound as claimed in claim 1 wherein t is 1, 2, 3, or 4;

R^1 is $-C(O)NR^7R^8$, $-C(O)-C_{1-6}alkanediylSR^9$, $-NR^{10}C(O)N(OH)R^9$, $-NR^{10}C(O)C_{1-6}alkanediylSR^9$, $-NR^{10}C(O)C{=}N(OH)R^9$ or another Zn-chelating-group wherein R^7 and R^8 are each independently selected from hydrogen, hydroxy, hydroxyC_{1-6}alkyl or aminoC_{1-6}alkyl;

R^2 is hydrogen, halo, hydroxy, amino, nitro, C_{1-6}alkyl, C_{1-6}alkyloxy, trifluoromethyl or di(C_{1-6}alkyl)amino;

-L- is a direct bond or a bivalent radical selected from C_{1-6}alkanediyl, C_{1-6}alkanediyloxy, amino or carbonyl;

R^4 is hydrogen, hydroxy, amino, hydroxyC_{1-6}alkyl, C_{1-6}alkyl, C_{1-6}alkyloxy, arylC_{1-6}alkyl, aminocarbonyl, aminoC_{1-6}alkyl, C_{1-6}alkylaminoC_{1-6}alkyl or di(C_{1-6}alkyl)aminoC_{1-6}alkyl;

 is a radical selected from (a-1), (a-3), (a-4), (a-5), (a-6), (a-7), (a-8), (a-9), (a-10), (a-11), (a-12), (a-13), (a-14), (a-15), (a-16), (a-17), (a-18), (a-19), (a-20), (a-21), (a-22), (a-23), (a-24), (a-25), (a-26), (a-28), (a-29), (a-30), (a-31), (a-32), (a-33), (a-34), (a-35), (a-36), (a-37), (a-38), (a-39), (a-40), (a-41), (a-42), (a-44), (a-45), (a-46), (a-47), (a-48) and (a-51);

each s is independently 0, 1, 2, 3 or 4;

R^5 is hydrogen; halo; hydroxy; amino; nitro; trihaloC_{1-6}alkyl; trihaloC_{1-6}alkyloxy; C_{1-6}alkyl; C_{1-6}alkyloxy; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkylsulfonyl; hydroxyC_{1-6}alkyl; aryloxy; di(C_{1-6}alkyl)amino; cyano; thiophenyl; furanyl; furanyl substituted with hydroxyC_{1-6}alkyl; benzofuranyl; imidazolyl; oxazolyl; oxazolyl substituted with aryl and C_{1-6}alkyl; C_{1-6}alkyltriazolyl; tetrazolyl; pyrrolidinyl; pyrrolyl; morpholinyl; C_{1-6}alkylmorpholinyl; piperazinyl; C_{1-6}alkylpiperazinyl; hydroxyC_{1-6}alkylpiperazinyl; C_{1-6}alkyloxypiperidinyl; pyrazoly; pyrazolyl substituted with one or two substituents selected from C_{1-6}alkyl or trihaloC_{1-6}alkyl; pyridinyl; pyridinyl substituted with C_{1-6}alkyloxy, aryloxy or aryl; pyrimidinyl; quinolinyl; indole; phenyl; or phenyl substituted with one or two substituents independently selected from halo, C_{1-6}alkyl, C_{1-6}alkyloxy or trifluoromethyl;

R^6 is hydrogen; halo; hydroxy; amino; nitro; trihaloC_{1-6}alkyl; trihaloC_{1-6}alkyloxy; C_{1-6}alkyl; C_{1-6}alkyloxy; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkylsulfonyl; hydroxyC_{1-6}alkyl; aryloxy; di(C_{1-6}alkyl)amino; cyano; pyridinyl; phenyl; or phenyl substituted with one or two substituents independently selected from halo, C_{1-6}alkyl, C_{1-6}alkyloxy or trifluoromethyl.

4. (Previously Presented) A compound as claimed in claim 1 wherein n is 1; t is 0 or 1; each Q is  ; each X is nitrogen; each Y is nitrogen; R^1 is –C(O)NH(OH); R^2 is hydrogen; -L- is a direct bond; each R^3 independently represents a hydrogen atom; R^4 is hydrogen;  is a radical selected from (a-6), (a-11), (a-20), (a-47) or (a-51); each s is independently 0, 1, or 4; and each R^5 and R^6 are independently selected from hydrogen; C_{1-6}alkyl; C_{1-6}alkyloxy; naphtalenylsulfonyl; or phenyl substituted with hydroxyC_{1-4}alkyl or morpholinylC_{1-4}alkyl.

5. (Currently Amended) A compound selected from the group consisting of: ~~compounds No. 3, No. 4, No. 8, No. 5, No. 7, No. 6 and No. 9.~~

 ; ~~No. 3~~	 ; ~~No. 4~~
 ~~No.8~~	 ; ~~No.5~~
 ; ~~No.7~~	 ; and ~~No.6~~
 : ~~No.9~~	

6. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound according to claim 1.

7. (Previously Presented) A process of preparing a pharmaceutical composition as claimed in claim 6 wherein the pharmaceutically acceptable carriers and the compound according to claim 1 are intimately mixed.

8. (Cancelled)

9. (Cancelled)

10. (Currently Amended) A process for preparing a compound as claimed in claim 1, <u>said method comprising:</u> ~~characterized by~~ reacting an intermediate of formula (II) with an ~~appropriate~~ acid~~, such as for example, trifluoro acetic acid,~~ yielding a hydroxamic acid of formula (I-a), wherein R^1 is –C(O)NH(OH)



11. (Currently Amended) A method of detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim <u>1</u>~~(I)~~ and a HDAC.

12. (Cancelled)